Navigation Links
Antibiotic resistance


Antibiotic resistance is the ability of a microorganism to withstand the effects of an antibiotic. Antibiotic resistance develops through mutation or plasmid exchange between bacteria of the same species. If a bacterium carries several resistance genes, it is called multiresistant or, informally, a superbug.

Contents

Causes

Antibiotic resistance is a consequence of evolution via natural selection. The antibiotic action is an environmental pressure; those bacteria which have a mutation allowing them to survive will live on to reproduce. They will then pass this trait to their offspring, which will be a fully resistant generation.

Several studies have demonstrated that patterns of antibiotic usage greatly affect the number of resistant organisms which develop. Overuse of broad-spectrum antibiotics, such as second and third generation cephalosporins, greatly hastens the development of methicillin resistance, even in organisms that have never been exposed to the selective pressure of methicillin per se. Other factors contributing towards resistance include incorrect diagnosis, unnecessary prescriptions, improper use of antibiotics by patients, and the use of antibiotics as livestock food additives for growth promotion.

Resistant pathogens

Staphylococcus aureus (colloquially known as "Staph aureus") is one of the major resistant pathogens. Found on the mucous membranes and the skin of around a third of the population, it is extremely adaptable to antibiotic pressure. It was the first bacterium in which penicillin resistance was found -- in 1947, just four years after the drug started being mass-produced. Methicillin was then the antibiotic of choice. MRSA (methicillin-resistant Staphylococcus aureus) was first detected in Britain in 1961 and is now "quite common" in hospitals. MRSA was responsible for 37% of fatal cases of blood poisoning in the UK in 1999, up from 4% in 1991. Half of all S. aureus infections in the US are resistant to penicillin, methicillin, tetracycline and erythromycin.

This left vancomycin as the only effective agent available at the time. However, VRSA (Vancomycin-resistant Staphylococcus aureus) was first identified in Japan in 1997 and has since been found in hospitals in England, France and the US. VRSA is also termed GISA (glycopeptide intermediate Staphylococcus aureus) or VISA (vancomycin intermediate Staphylococcus aureus), indicating resistance to all glycopeptide antibiotics.

A new class of antibiotics, oxazolidinones , became available in the 1990s, and the first commercially available oxazolidinone, linezolid, is comparable to vancomycin in effectiveness against MRSA. Linezolid-resistance in Staphylococcus aureus was reported in 2003.


Enterococcus faecium is another superbug found in hospitals: penicillin resistance was seen in 1983, vancomycin resistance (VRE) in 1987 and linezolid resistance (LRE) in the late 1990s.

Penicillin-resistant pneumonia (or pneumococcus, caused by Streptococcus pneumoniae) was first detected in 1967, as was penicillin-resistant gonorrhea. Resistance to penicillin substitutes is also known beyond S. aureus. By 1993 Escherichia coli was resistant to five fluoroquinolone variants. Mycobacterium tuberculosis is commonly resistant to isoniazid and rifampin and sometimes universally resistant to the common treatments. Other pathogens showing some resistance include Salmonella, Campylobacter, and Streptococci.

Alternatives to antibiotics

Prevention

Wash hands properly to reduce the chance of getting sick and spreading infection. Wash fruits and vegetables thoroughly. Avoid raw eggs and undercooked meat, especially in ground form. Do not demand antibiotics from your physician. When given antibiotics, take them exactly as prescribed and complete the full course of treatment; do not hoard pills for later use or share leftover antibiotics.

Vaccines

Vaccines do not suffer the problem of resistance. This is because a vaccine enhances the body's natural defenses, while an antibiotic operates separately from the body's normal defenses. Nevertheless, new strains may evolve that escape immunity induced by vaccines.

While theoretically promising, anti-staphylococcal vaccines have shown limited efficacy, because of immunological variation between Staphylococcus species, and the limited duration of effectiveness of the antibodies produced. Development and testing of more effective vaccines is under way.

Phage therapy

Phage therapy is a more recent alternative that can cope with the problem of resistance.

See also

External links


'"/>


(Date:11/4/2009)...obal Rainmakers, Inc., an intellectual property ho...ay announced that the company has exited its "stea...e its suite of technologies designed to leverage c...ring the past four years, the company has spent te...series of core--but expandable--technologies built...
(Date:11/4/2009)...coe Software, Inc., the commercial arm of the Open.../openmicroscopy.org ), is proud to announce its c...logy,s exciting new project titled "The Cell: An I...timulus grant through the National Institutes of H... of the American Reinvestment and Recovery Act, to...
(Date:11/3/2009)...r of the ocean, cruising thousands of miles in a s...ered that the sharks have maintained such a consis...nds of years the white sharks in the northeastern ...ulation genetically distinct from sharks elsewhere...ly mobile species," said Salvador Jorgensen, a pos...
Breaking Biology News(10 mins):Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 2Global Rainmakers Brings Cutting-Edge Biometric Security Products to Reality 3Glencoe Software to Support the ASCB 'Stimulus Grant' to Build Virtual Image Library of the Cell 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 2Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 3Tags reveal white sharks have neighborhoods in the north Pacific, say Stanford researchers 4The tourist trap 9540 1BELLUS Health reports results for first half of fiscal 2009 54277 1BELLUS Health reports results for first half of fiscal 2009 54277 2BELLUS Health reports results for first half of fiscal 2009 54277 3BELLUS Health reports results for first half of fiscal 2009 54277 4BELLUS Health reports results for first half of fiscal 2009 54277 5BELLUS Health reports results for first half of fiscal 2009 54277 6BELLUS Health reports results for first half of fiscal 2009 54277 7BELLUS Health reports results for first half of fiscal 2009 54277 8BELLUS Health reports results for first half of fiscal 2009 54277 9BELLUS Health reports results for first half of fiscal 2009 54277 10BELLUS Health reports results for first half of fiscal 2009 54277 11BELLUS Health reports results for first half of fiscal 2009 54277 12BELLUS Health reports results for first half of fiscal 2009 54277 13BELLUS Health reports results for first half of fiscal 2009 54277 14BELLUS Health reports results for first half of fiscal 2009 54277 15BELLUS Health reports results for first half of fiscal 2009 54277 16BELLUS Health reports results for first half of fiscal 2009 54277 17BELLUS Health reports results for first half of fiscal 2009 54277 18BELLUS Health reports results for first half of fiscal 2009 54277 19BELLUS Health reports results for first half of fiscal 2009 54277 20BELLUS Health reports results for first half of fiscal 2009 54277 21BELLUS Health reports results for first half of fiscal 2009 54277 22BELLUS Health reports results for first half of fiscal 2009 54277 23BELLUS Health reports results for first half of fiscal 2009 54277 24BELLUS Health reports results for first half of fiscal 2009 54277 25BELLUS Health reports results for first half of fiscal 2009 54277 26BELLUS Health reports results for first half of fiscal 2009 54277 27BELLUS Health reports results for first half of fiscal 2009 54277 28Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 1Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 2Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 3Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 4Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 5Cryo Cell Announces Strategic Partnership With S Evans Biosciences Inc 13512 6
...shade trees may improve crops, resistance to tempe...nges are expected to trigger, according to an arti.... The article, by Brenda B. Lin, Ivette Perfecto, ..., focuses on coffee production, although their con... important crops, including cocoa and tea, which a...
...Biometric Access Control Solution, ...., Sept. 30 BIO-key International,Inc. (OTC Bulle...ty,solutions and finger-based biometric identifica...nte"), a leading accounting and consultant firm, h...to secure their new,headquarters., Parente, headq...
...American Scientists (FAS) will reach new levels wi...te immunology video game through a generous grant ...d fun game is available for download at http://fa...next version of Immune Attack in February 2009," s...earning Technologies Program. "We,re interested i...
Other Biology News:Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 2Parente Randolph Secures Access to New Corporate Headquarters With BIO-key(R) Biometric Identification 3Entertainment Software Association Foundation awards grant to FAS for immune attack 2
Other biology definitionOther TagsTerrorism